Clinical trials: LAM
Hepatitis B, HIV Infection
Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients
This study will evaluate the safety and effectiveness of adding the experimental drug adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in HIV-infected patients with liver cirrhosis.
- Trial name
- NCT00013702
- Testing
- Adefovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
To compare the long-term virologic response to combination therapy with two protease inhibitors, i.e., nelfinavir (NFV) + saquinavir soft gel capsule (SQVsgc) and delavirdine (DLV) or combination lamivudine/zidovudine (3TC/ZDV…
- Trial name
- NCT00001094
- Testing
- Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir
- Where
- 17 sites in United States, Puerto Rico
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pregnancy During Breastfeeding, Lactational Amenorrhea Method
Emergency Contraception as a Back up of Lactational Amenorrhea Method(LAM)
Prolonged breast-feeding is an encouraged tradition in Egypt. Breastfeeding is associated with variable degrees of amenorrhea and infertility but there is a risk of resumption of fertility and therefore, of conception during…
- Trial name
- ECLAM (NCT01111929)
- Testing
- Counseling for LAM+ LNG-EC
- Volunteers
- 1,174 people
- Sponsor
- Assiut University
HIV Infections
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)[AS PER AMENDMENT 8/4/98: 50 copies/ml] between weeks 0 and 24.
- Trial name
- NCT00002215
- Testing
- Emivirine, Nelfinavir mesylate
- Where
- United States
- Sponsor
- Triangle Pharmaceuticals
HIV Infections
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
Human immunodeficiency virus (HIV)-1 infected participants receiving long-term therapy with lamivudine or emtricitabine (nucleoside reverse transcriptase inhibitors [NRTIs]) are at risk for the development of a mutation at…
- Trial name
- Resistance (NCT00312039)
- Testing
- Elvucitabine, Lamivudine
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infection
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA…
- Trial name
- HEAT (NCT00244712)
- Testing
- emtricitabine/tenofovir, abacavir/lamivudine
- Where
- 74 sites in United States, Puerto Rico
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
This study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Trial name
- NCT00057265
- Testing
- telbivudine or lamivudine
- Where
- 11 sites in United States, South Korea and 4 more
- Sponsor
- Novartis
HIV Infection
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and…
- Trial name
- NCT00094367
- Testing
- Abacavir/Lamivudine
- Where
- 178 sites in United States
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Lymphangioleiomyomatosis
Discovery of Sirolimus Sensitive Biomarkers in Blood
Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive disease. It usually affects women in the prime of their lives. It typically results in lung destruction.
- Trial name
- NCT03304678
- Testing
- Sirolimus 2mg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
The ANRS 12174 study is a clinical trial that will compare the efficacy and safety of prolonged infant peri-exposure prophylaxis (PEP) with Lopinavir/Ritonavir (LPV/r) versus Lamivudine to prevent HIV-1 transmission through…
- Trial name
- NCT00640263
- Testing
- lopinavir/ritonavir (LPV/r), Lamivudine (3TC)
- Where
- 4 sites in Burkina Faso, South Africa and 2 more
- Volunteers
- 1,500 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Palliative Care
Impact of Medicalized Residential Care (LAM) on the Development of Care Plans for Vulnerable Patients in Palliative Care
The aim of the research is to identify the factors influencing the development of care plans for vulnerable patients admitted to medicalized care facilities (LAM) and in palliative care.
- Trial name
- LAM-SP (NCT07342985)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
HIV Disease
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
The purpose of this study was to compare the use of lamivudine (3TC) or emtricitabine (FTC) alone vs. continuing a failing highly active antiretroviral therapy (HAART) regimen in HIV infected children, adolescents and young…
- Trial name
- P1094 (NCT01338025)
- Testing
- HAART regimen, 3TC or FTC monotherapy
- Where
- 17 sites in United States, Argentina and 3 more
- Volunteers
- 33 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Chronic Hepatitis B
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
- Trial name
- NCT00036608
- Testing
- Entecavir
- Where
- 39 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Tuberculosis
TB-LAM in the Diagnosis of TB
Tuberculosis (TB) is still the leading cause of death in HIV-infected patients. Early diagnosis of TB substantially improves the survival of HIV-infected patients.
- Conditions
- HIV Infections, Tuberculosis, Non-Tuberculous Mycobacterial Pneumonia
- Trial name
- NCT04600232
- Testing
- Alere TB-LAM
- Volunteers
- 400 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV Infections, Dyslipidemias
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
This is a randomised study of the effect of treatment with Combivir (zidovudine [AZT] and lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the development of abnormalities in lipid and glucose…
- Conditions
- HIV Infections, Dyslipidemias, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- NCT00192621
- Testing
- Combivir (zidovudine [AZT] / lamivudine [3TC]), Kaletra (lopinavir [LPVr])
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Healthy
Metabolomics Approach After Acute Intake of Grumixama Juice
Investigate the bioavailability of the main flavonoid, their colonic transformation and untargeted metabolites by an metabolomic approach following acute intake of a grumixama juice by humans.
- Trial name
- NCT02790658
- Testing
- Intake of grumixama juice
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Infection, Human Immunodeficiency Virus, HIV Infections
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (tenofovir…
- Trial name
- NCT02831764
- Testing
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Where
- 105 sites in United States, Argentina and 16 more
- Volunteers
- 722 people
- Sponsor
- ViiV Healthcare
Hiv, HIV-1-infection
Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test
The purpose of this study is to evaluate the efficacy of DTG + 3TC versus DTG + TDF/FTC over 48 weeks in HIV-1 naive patients in a real life setting with no baseline HIV genotypic resistance testing available.
- Trial name
- D2ARLING (NCT04549467)
- Testing
- Lamivudine 300 MG, Emtricitabine / Tenofovir Disoproxil Pill
- Where
- Argentina
- Volunteers
- 244 people
- Sponsor
- Fundacion IDEAA
Human Immunodeficiency Virus (HIV)
ComBaCaL HIV Prevention TwiCs
This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for…
- Trial name
- CoPrev (NCT07581600)
- Testing
- CoPrev model, Referral to the nearest responsible health facility
- Where
- 2 sites in Lesotho, Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
HIV Infections
A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children
The study examines the safety and effectiveness of ritonavir (an anti-HIV drug), alone and in combination with other anti-HIV drugs, in HIV-positive children under 2 years of age.
- Trial name
- NCT00000952
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)